Lin Zaijun, Song Dianwen, Wei Haifeng, Yang Xinghai, Liu Tielong, Yan Wangjun, Xiao Jianru
Department of Bone Tumor Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, China.
J Cancer Res Clin Oncol. 2016 Jan;142(1):239-46. doi: 10.1007/s00432-015-2028-9. Epub 2015 Aug 15.
A number of studies have demonstrated that microRNAs play a critical role in osteosarcoma progression, therapy and drug resistance. MicroRNA-202 has proven to be dysregulated in many human cancer studies. This study aimed to explore miR-202 contributions to drug resistance in osteosarcoma.
miR-202 expression was measured by real-time PCR in patient tissues, cell lines or cells treated with TGF-β1, using siRNA to knock down the expression of Smad2, Smad3 and Smad4. miR-202 mimics, inhibitor and scramble siRNA were transfected into osteosarcoma cells to observe effects on cell apoptosis and drug resistance. Moreover, relationships of miR-202 level with PDCD4 were investigated by luciferase reporter assay, real-time PCR and Western blotting.
We found that miR-202 is overexpressed in osteosarcoma tissues when compared with normal human osteoblasts and TGF-β1 can induce the expression of miR-202. Transfection of miR-202 mimics into osteosarcoma cell lines significantly promotes chemotherapy resistance by targeting PDCD4, a tumor suppressor which is involved in apoptosis. In contrast, transfection of miR-202 inhibitor enhances the drug sensitivity and apoptosis.
This study provides new insights into miRNA-202 in osteosarcoma as a potential molecular target for chemotherapy.
多项研究表明,微小RNA在骨肉瘤进展、治疗及耐药性中起关键作用。在许多人类癌症研究中,已证实微小RNA-202表达失调。本研究旨在探讨miR-202在骨肉瘤耐药性中的作用。
采用实时定量PCR检测患者组织、细胞系或经转化生长因子-β1(TGF-β1)处理的细胞中miR-202的表达,使用小干扰RNA(siRNA)敲低Smad2、Smad3和Smad4的表达。将miR-202模拟物、抑制剂及乱序siRNA转染至骨肉瘤细胞,观察其对细胞凋亡和耐药性的影响。此外,通过荧光素酶报告基因检测、实时定量PCR及蛋白质免疫印迹法研究miR-202水平与程序性细胞死亡蛋白4(PDCD4)的关系。
我们发现,与正常人成骨细胞相比,miR-202在骨肉瘤组织中过表达,且TGF-β1可诱导miR-202表达。将miR-202模拟物转染至骨肉瘤细胞系,通过靶向参与细胞凋亡的肿瘤抑制因子PDCD4,显著促进化疗耐药性。相反,转染miR-202抑制剂可增强药物敏感性并促进细胞凋亡。
本研究为miR-202作为骨肉瘤化疗潜在分子靶点提供了新见解。